Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Spritzler

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
The International Journal of Biostatistics|March 17, 2010
Two-sample tests of area-under-the-curve in the presence of missing dataJohn Spritzler, Victor G DeGruttola, Lixia Pei
Journal of Acquired Immune Deficiency Syndromes (1999)|June 27, 2012
Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruptionJonathan Z Li, Julie A Christensen, Hongying Wang, et al.
Clinical Trials (London, England)|November 11, 2005
A reporting tool for real-time assessment of study data availabilityRonald J Bosch, Casey Pierce, John Spritzler, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 1, 2005
Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infectionDonna Mildvan, John Spritzler, Sidney E Grossberg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2003
Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials GroupJohn Spritzler, Donna Mildvan, Aleksandra Russo, et al.
AIDS (London, England)|May 11, 2002
A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infectionMark A Jacobson, John Spritzler, Alan Landay, et al.
AIDS Research and Human Retroviruses|June 22, 2010
Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavirKeith W Crawford, John Spritzler, Robert C Kalayjian, et al.
Clinical Immunology (Orlando, Fla.)|November 15, 2008
The effect of aging on T-regulatory cell frequency in HIV infectionAllan R Tenorio, John Spritzler, Jeffrey Martinson, et al.
The Journal of Infectious Diseases|November 19, 2003
Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimenAlan L Landay, John Spritzler, Harold Kessler, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2010
Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIVTimothy W Schacker, Ronald J Bosch, Kara Bennett, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
The International Journal of Biostatistics|March 17, 2010
Two-sample tests of area-under-the-curve in the presence of missing dataJohn Spritzler, Victor G DeGruttola, Lixia Pei
Journal of Acquired Immune Deficiency Syndromes (1999)|June 27, 2012
Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruptionJonathan Z Li, Julie A Christensen, Hongying Wang, et al.
Clinical Trials (London, England)|November 11, 2005
A reporting tool for real-time assessment of study data availabilityRonald J Bosch, Casey Pierce, John Spritzler, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 1, 2005
Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infectionDonna Mildvan, John Spritzler, Sidney E Grossberg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2003
Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials GroupJohn Spritzler, Donna Mildvan, Aleksandra Russo, et al.
AIDS (London, England)|May 11, 2002
A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infectionMark A Jacobson, John Spritzler, Alan Landay, et al.
AIDS Research and Human Retroviruses|June 22, 2010
Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavirKeith W Crawford, John Spritzler, Robert C Kalayjian, et al.
Clinical Immunology (Orlando, Fla.)|November 15, 2008
The effect of aging on T-regulatory cell frequency in HIV infectionAllan R Tenorio, John Spritzler, Jeffrey Martinson, et al.
The Journal of Infectious Diseases|November 19, 2003
Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimenAlan L Landay, John Spritzler, Harold Kessler, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2010
Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIVTimothy W Schacker, Ronald J Bosch, Kara Bennett, et al.
Pageof 3